BACKGROUND
gastric cancer (GC).Pyrotinib, tumor, breast cancer
PROLIFERATION, TUMOR, BREAST CANCER
Human epidermal growth factor receptor 2 (HER2) was a key therapeutic target in gastric cancer (GC).Pyrotinib was a novel oral, irreversible pan‐ErbB small‐molecular TKI blocking HER1, HER2, and HER4, which was approved in HER2‐positive breast cancer (BC). And it has been reported that pyrotinib could inhibit the proliferation of gastric cells overexpressing HER2 (NCI‐N87 and BT474 cell line) in vitro.Docetaxel, a broad‐spectrum phase M cycle‐specific cytotoxic drug which promotes the polymerization of tubules into stable microtubules, inhibits their polymerization and significantly reduces the tumor proliferation.Hereby, we first performed a multicenter, phase I study to prospectively assess the safety and pharmacokinetic (PK) characteristics of pyrotinib alone or plus docetaxel in refractory HER2‐positive GC patients, and explore the preliminary antitumor activity as well.